A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5\*10\^10 viral particles (vp) and 1\*10\^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults.
Epistemonikos ID: cd0d5898b5ea9c5261663699d5b87cdfbb6cf2f2
First added on: May 21, 2024